Legend Biotech

LEGNPhase 2

Legend Biotech is a leader in the development of innovative cell therapies, with a primary focus on treating hematologic malignancies and solid tumors. Its landmark achievement is the development and commercialization of CARVYKTI, a BCMA-directed CAR-T therapy approved for relapsed/refractory multiple myeloma, which it co-develops and co-commercializes with Janssen Biotech, Inc. The company leverages its integrated cell therapy platform to build a diversified pipeline, including allogeneic and armored CAR-T candidates, and maintains strategic R&D operations in the U.S., China, and Europe.

Market Cap

$3.2B

Employees

1000-2000

Focus

Cell & Gene Therapy

LEGN · Stock Price

USD 17.4119.47 (-52.79%)

Historical price data

AI Company Overview

Technology Platform

Integrated cell therapy platform for developing autologous and allogeneic chimeric antigen receptor T-cell (CAR-T) therapies, encompassing proprietary CAR design, manufacturing, and target discovery.

Pipeline Snapshot

36 drugs in pipeline

Drug	Indication	Stage
LCAR-B38M CAR-T Cell	Multiple Myeloma	Phase 2
LCAR-B38M CAR-T cell injection	Refractory or Relapsed Multiple Myeloma	Phase 1/2
LUCAR-G39D cells product	B-Cell Non-Hodgkin Lymphoma-Recurrent	Phase 1
LB1901	T-Cell Lymphoma	Phase 1
LUCAR-DKS1 NK cells	Relapsed/Refractory Autoimmune Diseases	Phase 1

Funding History

Total raised: $537M

IPO$487MUndisclosedJun 5, 2020

Series A$50MGICJan 15, 2018

Opportunities

Significant growth opportunity lies in expanding CARVYKTI's label into earlier lines of multiple myeloma treatment, potentially doubling or tripling the addressable patient population.

The pipeline targeting solid tumors (lung, gastric cancers) represents entry into much larger oncology markets.

Successfully developing an allogeneic (off-the-shelf) platform could revolutionize cell therapy accessibility and economics.

Risk Factors

Key risks include intense competition in multiple myeloma from other CAR-Ts and bispecific antibodies, potential long-term safety issues with CARVYKTI, the high cost and complexity of cell therapy manufacturing and logistics, and the clinical failure of earlier-stage pipeline candidates in challenging solid tumor indications.

Competitive Landscape

Primary competitor in multiple myeloma is Bristol Myers Squibb's Abecma (CAR-T), with additional competition from bispecific antibodies (J&J's Tecvayli, Pfizer's Elrexfio). In pipeline solid tumor indications, Legend will compete against other biotechs developing CAR-Ts (e.g., Gilead/Kite) and a wide array of targeted therapies and immunotherapies. Differentiation is based on depth of response, proprietary CAR designs, and the Janssen partnership.

Publications

Pipeline